Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 8/20 | 0.41 |
| ▸ | TLR7 | Q9NYK1 | 15/20 | 0.40 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4314466 | 0.99 | TLR7 (0.41) | TLR8TLR7NUDT1MEN1KMT2A | |
| SCHEMBL3871007 | 0.87 | TLR7 (0.39) | TLR8TLR7NUDT1RXFP1 | |
| SCHEMBL4324657 | 0.87 | HDAC4 (0.37) | TLR8TLR7NUDT1MEN1KMT2A | |
| SCHEMBL4308944 | 0.87 | TLR8 (0.42) | TLR8TLR7NUDT1MEN1KMT2A | |
| SCHEMBL6099996 | 0.87 | TLR8 (0.49) | TLR8TLR7NUDT1MEN1KMT2A | |
| SCHEMBL4314464 | 0.86 | TLR8 (0.42) | TLR8TLR7NUDT1MEN1KMT2A | |
| SCHEMBL5616943 | 0.85 | TLR8 (0.46) | TLR8TLR7NUDT1MEN1KMT2A | |
| SCHEMBL3168166 | 0.85 | TLR8 (0.46) | TLR8TLR7NUDT1MEN1KMT2A | |
| SCHEMBL5616927 | 0.84 | TLR8 (0.46) | TLR8TLR7NUDT1MEN1KMT2A | |
| SCHEMBL4308938 | 0.84 | TLR8 (0.47) | TLR8TLR7NUDT1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8735421-B2 | Imidazoquinolinyl sulfonamides | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2014-05-27 | — | — | US | disclosed |
| US-20090062272-A1 | IMIDAZOQUINOLINYL SULFONAMIDES | 3M INNOVATIVE PROPERTIES COMPANY | 2009-03-05 | — | — | US | disclosed |
| CN-101014596-A | Imidazoquinolinylsulfonamides, imidazopyridinylsulfonamides, and imidazo-1, 5-naphthyridinylsulfonamides | 3M INNOVATIVE PROPERTIES CO (US) | 2007-08-08 | — | — | CN | disclosed |
| EP-1699788-A2 | IMIDAZOQUINOLINYL, IMIDAZOPYRIDINYL AND IMIDAZONAPHTHYRIDINYL SULFONAMIDES | 3M Innovative Properties Company (US) | 2006-09-13 | — | — | EP | disclosed |
| WO-2005066169-A2 | IMIDAZOQUINOLINYL, IMIDAZOPYRIDINYL, AND IMIDAZONAPHTHYRIDINYL SULFONAMIDES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2005-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062272-A1 | IMIDAZOQUINOLINYL SULFONAMIDES | IL2, EIF2AK2, IFNG | TLR8 106/4885TLR7 167/4885NUDT1 1301/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.